Kaewbut Piranee, Kosachunhanun Natapong, Phrommintikul Arintaya, Chinwong Dujrudee, Hall John J, Chinwong Surarong
PhD's Degree Program in Pharmacy, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao 56000, Thailand.
Healthcare (Basel). 2022 Sep 1;10(9):1673. doi: 10.3390/healthcare10091673.
Patients with type 2 diabetes mellitus (T2DM) can be affected by clinical inertia, leading to abysmal results. Studies on a suitable timeframe for treatment intensification remain scarce-especially outside of developed countries. This study aimed to explore the association between time to treatment intensification and diabetes-related complications. A database from a tertiary care hospital in Thailand was retrieved in order to conduct a retrospective cohort study for the years 2011-2017. This study comprised outpatients with T2DM presenting an HbA1c of ≥7.0%. Eligible patients were divided into three groups based on the time of treatment intensification: no delayed treatment intensification, treatment intensification within 6 months, and treatment intensification after 6 months. A Cox proportional hazards model was used to investigate the association between time to treatment intensification and diabetes-related complications. A total of 686 patients were included in the final analysis. During 6.5 years of median follow-up, the group with treatment intensification within 6 months was more strongly associated with diabetic nephropathy compared to the group with no delayed treatment intensification (adjusted HR 2.35; 95%CI 1.35-4.09). Our findings reveal that delaying treatment intensification by even 6 months can increase the likelihood of diabetic nephropathy compared to no delayed treatment intensification. We suggest that patients with T2DM whose blood glucose levels are outside the target range promptly receive treatment intensification.
2型糖尿病(T2DM)患者可能会受到临床惰性的影响,导致结果很不理想。关于治疗强化合适时间框架的研究仍然很少,尤其是在发达国家以外。本研究旨在探讨治疗强化时间与糖尿病相关并发症之间的关联。为了进行一项针对2011 - 2017年的回顾性队列研究,检索了泰国一家三级护理医院的数据库。本研究纳入了糖化血红蛋白(HbA1c)≥7.0%的T2DM门诊患者。符合条件的患者根据治疗强化时间分为三组:无延迟治疗强化、6个月内治疗强化和6个月后治疗强化。采用Cox比例风险模型研究治疗强化时间与糖尿病相关并发症之间的关联。最终分析共纳入686例患者。在中位随访6.5年期间,与无延迟治疗强化组相比,6个月内治疗强化组与糖尿病肾病的关联更强(调整后风险比2.35;95%置信区间1.35 - 4.09)。我们的研究结果表明,与无延迟治疗强化相比,即使延迟6个月进行治疗强化也会增加患糖尿病肾病的可能性。我们建议血糖水平超出目标范围的T2DM患者应及时接受治疗强化。